Esperion Therapeutics, Inc. (ESPR) 8-K Current Report: March 3, 2026
Filed: March 3, 2026
Health Care
Pharmaceutical PreparationsEsperion Therapeutics, Inc. (ESPR) 8-K current report filed with SEC EDGAR on March 3, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items2 items
- Item 1.01: Entry into a Material Definitive Agreement
- Item 7.01: Regulation FD Disclosure
Esperion Therapeutics, Inc. 8-K Mar 3, 2026 Event Analysis
Item 1.01 · Entry into a Material Definitive Agreement
- • Esperion acquiring Corstasis Therapeutics via cash merger for $75M upfront, closing deadline May 1, 2026
- • Total deal value up to $255M including $180M in regulatory/commercial milestone payments plus royalties
- • All-cash transaction; Corstasis shareholders, option holders, and RSU holders receive pro rata cash payouts
- • Corstasis becomes wholly-owned subsidiary; deal structured with escrow/expense accounts subject to post-closing purchase price adjustment
- • Strategic bet on Corstasis pipeline — milestone triggers tied to regulatory approvals and future product sales signal potential new revenue streams for ESPR
Item 7.01 · Regulation FD Disclosure
- • Esperion (ESPR) entering merger with Corstasis — deal announced March 3, 2026
- • Investor call held 8:00 a.m. ET March 3 to discuss transaction terms and strategic rationale
- • Full deal details in Exhibit 99.1 (press release) and Exhibit 99.2 (supplemental presentation)
Other Esperion Therapeutics, Inc. 8-K Filings
Get deeper insights on Esperion Therapeutics, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.